Clinical Trial Update: Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease [Phase 3]

View source ↗

Summary

Continued safety monitoring update for solanezumab (LY2062430) in Alzheimer's disease under a Phase 3 study; the trial is terminated with results posted in 2018…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Solanezumab (solanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2018-05-03